Susheel Kodali

Susheel Kodali

Auto-generated profile, based on publicly available information

Susheel Kodali

New York-Presbyterian Hospital/Columbia University Medical Center, New York, New York, United States

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in The American Journal of Cardiology
Verified
Journal Article
Closed access
SASaif Anwaruddin
Saif Anwaruddin
NDNimesh D. Desai
Nimesh D. Desai
WSWilson Y. Szeto
Wilson Y. Szeto
JHJames B. Hermiller
James B. Hermiller
PSPaul Sorajja
Paul Sorajja
MRMichael J. Reardon
Michael J. Reardon

17 June 2021 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
RHRebecca T Hahn
Rebecca T Hahn
SKSusheel K Kodali
Susheel K Kodali
Advanced intra-procedural imaging techniques have been integral to technical and procedural success transcatheter devices. A novel leaflet approximation therapy, the PASCAL Transcatheter Valve Repair System (Edwards Lifesciences, Irvine, CA, USA) has demonstrated high procedural success, acceptable safety, and significant clinical improvement in patients with severe mitral and tricuspid regurgitation and has CE mark approval in Europe with pivotal trials underway in the USA. This review outlines the pre-procedural imaging views and advanced transoesophageal imaging protocols both mitral and tricuspid valve device implantation.

28 December 2019 in European Heart Journal
Verified
Journal Article
Open access
PDF file
SCShmuel Chen
Shmuel Chen
BRBjorn Redfors
Bjorn Redfors
BOBrian P O’nEill
Brian P O’nEill
MCMarie-Annick Clavel
Marie-Annick Clavel
PPPhilippe Pibarot
Philippe Pibarot
BLBrian R Lindman
Brian R Lindman
B-type natriuretic peptide (BNP) is a cardiac neurohormone that is secreted in response to ventricular volume expansion and pressure overload. There are conflicting data regarding the association between BNP levels and outcomes after transcatheter aortic valve replacement (TAVR). We therefore sought to assess the association between baseline BNP and adverse outcomes in patients with symptomatic, severe aortic stenosis (AS), and left ventricular ejection fraction (LVEF) ≥50%, undergoing TAVR in the PARTNER 2 Trial and Registry. A total of 1782 patients were included in the analysis, and BNP was evaluated both as a continuous log-transformed value and by a priori categories: low (<50 pg/mL), normal (≥50 and <100 pg/mL), moderately elevated (≥100 and <400 pg/mL), or markedly elevated (≥400 pg/mL). Clinical outcomes from discharge to 2 years were compared between patients according to their baseline BNP level, using Kaplan–Meier event rates and multivariable Cox proportional hazards regression models. After adjustment, spline curves revealed a non-linear association between log-transformed BNP and all-cause and cardiovascular mortality in which both the lowest and highest values were associated with increased mortality. Two-year all-cause mortality rates for those with low (n = 86), normal (n = 202), moderately elevated (n = 885), and markedly elevated (n = 609) baseline BNP were 20.0%, 9.8%, 17.7%, and 26.1%, respectively. In adjusted models, compared to a normal baseline BNP, low [adjusted hazard ratio (HR) 2.6, 95% confidence interval (CI) 1.3–5.0, P-value 0.005], moderately elevated (adjusted HR 1.6, 95% CI 1.0–2.6, P-value 0.06), and markedly elevated (adjusted HR 2.1, 95% CI 1.3–3.5, P-value 0.003) BNP were associated with increased all-cause mortality, driven by cardiovascular mortality. In a large cohort of patients with severe symptomatic AS and preserved LVEF undergoing TAVR, all-cause and cardiovascular mortality rates at 2 years were higher in patients with low and markedly elevated BNP levels. https://clinicaltrials.gov/ unique identifier #NCT01314313, #NCT02184442, #NCT03222128, and #NCT03222141.

22 May 2020 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
SCShmuel Chen
Shmuel Chen
BRBjorn Redfors
Bjorn Redfors
ACAaron Crowley
Aaron Crowley
OBOri Ben-Yehuda
Ori Ben-Yehuda
MSMatthew Summers
Matthew Summers
MLMartin Leon
Martin Leon
Aims Heart failure (HF) hospitalization prior to transcatheter aortic valve replacement (TAVR) is associated with increased post‐procedural mortality. We sought to assess the association between recent (≤6 months) HF hospitalization and long‐term adverse outcomes in patients with symptomatic, severe aortic stenosis, undergoing TAVR in the PARTNER 2 trial and registries. Methods and results Intermediate to high or even prohibitive risk patients who underwent TAVR in the PARTNER 2 trial and registries were included in the analysis. Clinical outcomes at 30 days and 2 years were compared between patients according to whether they were recently hospitalized for HF, using Kaplan–Meier event rates and study‐stratified multivariable Cox proportional hazards regression models. A sensitivity analysis was conducted using propensity score matching. Of 3988 patients (99.8%) with available information on recent HF hospitalization, 1622 patients (40.7%) were hospitalized for HF symptoms during the 6 months prior to TAVR. After multivariable adjustments, recent HF hospitalization was associated with increased all‐cause mortality at 30 days [adjusted hazard ratio (HR) 1.63, 95% confidence interval (CI) 1.07–2.48, P = 0.02] and 2 years (adjusted HR 1.30, 95% CI 1.13–1.49, P = 0.0003), which was driven by increased cardiovascular mortality. Infective endocarditis rate at 2 years was also higher in patients with recent HF hospitalization (adjusted HR 2.35, 95% CI 1.38–4.01, P = 0.002). These results remained consistent when propensity score matching was used. Conclusion In a large cohort of patients with severe symptomatic aortic stenosis from the PARTNER 2 trial and registries, all‐cause and cardiovascular mortality as well as infective endocarditis rates at 2 years were higher in patients with recent HF hospitalization.

17 August 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
TOTakuya Ogami
Takuya Ogami
PKPaul Kurlansky
Paul Kurlansky
HTHiroo Takayama
Hiroo Takayama
YNYuming Ning
Yuming Ning
ZAZiad Ali
Ziad Ali
IGIsaac George
Isaac George
Background: Aortic stenosis is prevalent in end‐stage renal disease. Transcatheter aortic valve replacement (TAVR) is a plausible alternative for surgical aortic valve replacement. However, little is known regarding long‐term outcomes in patients with end‐stage renal disease who undergo TAVR. Methods and Results: We identified all patients with end‐stage renal disease who underwent TAVR from 2011 through 2016 using the United States Renal Data System. The primary end point was 5‐year mortality after TAVR. Factors associated with 1‐ and 5‐year mortality were analyzed. A total of 3883 TAVRs were performed for patients with end‐stage renal disease. Mortality was 5.8%, 43.7%, and 88.8% at 30 days, 1 year, and 5 years, respectively. Case volumes increased rapidly from 17 in 2011 to 1495 in 2016. Thirty‐day mortality demonstrated a dramatic reduction from 11.1% in 2012 to 2.5% in 2016 ( P =0.01). Age 75 or older (hazard ratio [HR], 1.14; 95% CI, 1.05–1.23 [ P =0.002]), body mass index <25 (HR, 1.18; 95% CI, 1.08–1.28 [ P <0.001]), chronic obstructive pulmonary disease (HR, 1.25; 95% CI, 1.1–1.35 [ P <0.001]), diabetes mellitus as the cause of dialysis (HR, 1.22; 95% CI, 1.11–1.35 [ P <0.001]), hypertension as the cause of dialysis (HR, 1.17; 95% CI, 1.06–1.29 [ P =0.004]), and White race (HR, 1.17; 95% CI, 1.06–1.3 [ P =0.002]) were independently associated with 5‐year mortality. Conclusions: Short‐term outcomes of TAVR in patients with end‐stage renal disease have improved significantly. However, long‐term mortality of patients on dialysis remains high.

6 January 2024 in The American Journal of Medicine
Verified
Journal Article
Closed access
AGAakriti Gupta
Aakriti Gupta
MMMakoto Mori
Makoto Mori
YWYun Wang
Yun Wang
SPShubhadarshini G. Pawar
Shubhadarshini G. Pawar
TVTorsten Vahl
Torsten Vahl
HKHarlan M. Krumholz
Harlan M. Krumholz